Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
Grew full-year revenue to between $358 million and $359 million, an increase of 21% Acquisition broadens Veracyte’s presence across the cancer care continuum... Read more.
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024
– Data anticipated in Q1 2024 from studies of STK-001 for the treatment of Dravet syndrome – – End of Phase 1/2a study results and OLE data from patients receiving... Read more.
JBL Dives into Pure Bliss with the JBL Soundgear Sense and JBL Tune 310C
JBL’s Air Conduction Technology redefines audio excellence, setting the stage for unforgettable listening experiences LAS VEGAS–(BUSINESS WIRE)–JBL,... Read more.
E-Commerce Ecosystem in Latin America, 2024: Comprehensive Report Unveils the Future of Digital Commerce – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “E-Commerce Ecosystem in Latin America, 2024: Uncovering Opportunities and Embracing the Future” report has been... Read more.
MindMed Announces Business Update and Anticipated Milestones for 2024
— Recently announced statistically significant and clinically meaningful topline Phase 2b data for MM-120 in Generalized Anxiety Disorder (GAD) position for... Read more.
Medable’s New Intelligent Automation Capabilities Cut Clinical Trial Technology Deployment Timelines By 50%
AI-powered* platform takes eCOA off the critical path to study startup for life sciences industry PALO ALTO, Calif.–(BUSINESS WIRE)–#biotech—Medable... Read more.
Medable’s New Intelligent Automation Capabilities Cut Clinical Trial Technology Deployment Timelines By 50%
AI-powered* platform takes eCOA off the critical path to study startup for life sciences industry PALO ALTO, Calif.–(BUSINESS WIRE)–#biotech—Medable... Read more.
Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028
– Intravenous (“IV”) CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as a short-acting,... Read more.
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer... Read more.
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer
Portfolio of Clinical and Preclinical Programs, Including Lead Product Candidate ARX517, a Prostate-Specific Membrane Antigen (PSMA)-Targeting Antibody Drug Conjugate... Read more.